<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>米内网 | wechat-feeds</title><link>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</link><description>米内网是中国领先的集医药健康产业研究、医院市场研究、零售市场研究、商业渠道研究、互联网在线医药健康信息服务于一体的综合性专业信息服务平台。目前拥有七项数据分析技术获国家专利，每月收集数据3000多万条，有63个专业数据库为医药健康行业服务。</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 18 Feb 2021 11:56:07 +0800</pubDate><image><url>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</url><title>米内网 | wechat-feeds</title><link>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>【砥砺2021】净利润从4000万到28亿！苑东、科兴……26家药企“抢滩”科创板，36家在路上</title><link>https://mp.weixin.qq.com/s/AILw3LQedZhVfBllHYI8Dw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/HKOy4YsExruvN1pYUr3WuwthnH60PXTj23JIW4RhYjWPdqyurgUJsibzVScK5SmbfuJItgUZJKYmweQhZ4XwMDg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>为A股市场注入优质企业]]></content:encoded><pubDate>Thu, 18 Feb 2021 08:57:19 +0800</pubDate></item><item><title>【砥砺2021】科伦、东阳光药、正大天晴......12个重磅首仿将获批，哄抢超$10亿品种</title><link>https://mp.weixin.qq.com/s/qIK8vFdcGDky8x7a5lvsMg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/HKOy4YsExru6rxWyBib9mJUT1UfAwbuQ41AGUoBdN6DsDaLHCuNIptD4Oxr4iaz57OubyeuViccyYXEeWSICciaO5A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>2021年首仿获批预测]]></content:encoded><pubDate>Wed, 17 Feb 2021 08:46:34 +0800</pubDate></item><item><title>【砥砺2021】13款1类新药亮了！恒瑞、海正、和黄、亚盛……将陆续获批！你最期待谁？</title><link>https://mp.weixin.qq.com/s/52wRdR3eFKpeEQnNcSGVkw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/HKOy4YsExru8jupe7ozncJhvUPVKjhRHW0QhmmMeVLbCDKd4ibpD0ial7OtLN7qlciborkZ7CHUOkNSmWEs5Z93Pw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>1类新药大爆发]]></content:encoded><pubDate>Tue, 16 Feb 2021 08:42:31 +0800</pubDate></item><item><title>【砥砺2021】“政策+资本”强势围攻药店圈，7大预测助推行业新蜕变</title><link>https://mp.weixin.qq.com/s/-cs6GVKb-9n9q96RMV0NgQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/HKOy4YsExruvN1pYUr3WuwthnH60PXTjekT5Cr1jLzNGvBiaxG83ibx3sPRecJicka1t9tQDsfLLzJPu3kzfbyClQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药店圈风云岁月]]></content:encoded><pubDate>Mon, 15 Feb 2021 08:39:03 +0800</pubDate></item><item><title>【砥砺2021】国内CRO行业N个趋势：打通上下游、优质标的渐少、新技术打造服务高地</title><link>https://mp.weixin.qq.com/s/SeOqRoSYKI2XbzLOWl06kw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/HKOy4YsExruvN1pYUr3WuwthnH60PXTjA76uXSQrWuxrOFHK5WDiaw8TUBDqYr0nV8XGxWib91ZCjE66Nr3zaIeQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>CRO已成行业发展关键力量]]></content:encoded><pubDate>Sun, 14 Feb 2021 08:47:00 +0800</pubDate></item></channel></rss>